Data from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7565446
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
551
Citations
13
h-index
13
i10-index
Shannon Breen is an academic researcher from AstraZeneca (United States). The author has contributed to research in topics: CAR-T cell therapy research & Monoclonal and Polyclonal Antibodies Research & HER2/EGFR in Cancer Research. The author has an h-index of 13, co-authored 47 publications.
Click to start Chat